{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Iodine_I_131_Rituximab",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A radioimmunoconjugate comprised of rituximab, a recombinant chimeric monoclonal antibody directed against the CD20 antigen, and labeled with iodine I 131 with potential antineoplastic activity. The antibody moiety of iodine I 131 rituximab binds to the CD20 antigen thereby delivering cytotoxic iodine I 131 specifically to cancer cells expressing CD20. The CD20 antigen, a hydrophobic transmembrane protein, is expressed on normal pre-B and mature B lymphocytes.",
    "fdaUniiCode": "K2I4B6I9L1",
    "identifier": "C102981",
    "preferredName": "Iodine I 131 Rituximab",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129819",
      "C2124"
    ],
    "synonyms": [
      "(131)I-Rituximab",
      "131I-Rituxan",
      "Iodine I 131 Rituximab",
      "RITUXIMAB I-131"
    ]
  }
}